卡维地洛对代谢综合征患者代谢指标的影响研究

目的:研究卡维地洛对代谢综合征患者血糖、血脂等代谢指标的影响。方法:入选60例符合代谢综合征诊断标准的轻度、中度高血压患者,并随机分为卡维地洛组和美托洛尔治疗组。在有效控制血压的同时,测量基础状态及接受治疗90天后的血糖、血胰岛素、及血脂水平等代谢指标。结果:用药前后,卡维地洛组胰岛素敏感性有所改善,美托洛尔组胰岛素敏感性无明显变化;用药后,美托洛尔组高密度脂蛋白(HDL-C)水平下降,而卡维地洛组HDL水平变化不明显;卡维地洛组用药后载脂蛋白-A(apo-A)水平明显升高,而美托洛尔组无明显变化;其余代谢指标两组用药前后均未见明显变化。结论:卡维地洛对代谢综合征患者有效降压的同时,对其代谢指标无负面影响。

The Effect of Carvedilol on Metabolic Parameters in Patients With Metabolic Syndrome

Objective To explore the effect of cavedilol treatment on metabolic parameters in metabolic syndrome. Methods A total of 60 patients with stage1-2 hypertension who fulfilled at least 3 of the metabolic syndrome criteria proposed by NCEP-ATPⅢ were included in this study. Patients were randomly assigned to receive daily treatment with carvedilol and metoprolol. The biochemical parameters and insulin sensitivity based on the HOMA-IR model were evaluated at baseline and at the end of treatment. Results A significant decrease in insulin resistance (HOMA-IR) in carvedilol group compared to the metoprolol group ( percent change -6.2±0.2 vs. +0.5±1.3, P<0.05). A significant decrease in HDL cholesterol levels occurred in the metoprolol group compared to the carvedilol group (percent change: -6.7±10.2 vs.-0.5±11.3, P<0.05). A significant increase in apolipoprotein A1 level was observed in the carvedilol group compared to the metoprolol group (percent change: +5.7±9.7 vs. -0.7±12.6, P<0.05). There were no significant differences between the two groups respect to other parameters. Conclusion It is concluded antihypertensive pressure without adversely affecting metabolic parameters.